# Tracon Pharmaceuticals

Source: https://onco.cc/companies/tracon/  
OnCo record `tracon` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tracon was a San Diego biotech whose endoglin antibody carotuximab failed a phase 3 trial in angiosarcoma and whose subcutaneous PD-L1 antibody envafolimab missed in sarcoma; it wound down in 2024.

## Summary

Tracon Pharmaceuticals, based in San Diego, developed carotuximab (TRC105), an antibody against endoglin on tumour blood vessels, which failed the phase 3 TAPPAS trial with pazopanib in angiosarcoma in 2019, and then in-licensed the subcutaneous PD-L1 antibody envafolimab, whose ENVASARC trial in undifferentiated pleomorphic sarcoma did not meet its endpoint in 2023. The company ceased operations in 2024. Its trials remain on ClinicalTrials.gov under Tracon as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Tracon Pharmaceuticals Inc.; TRACON
- Tags: ctgov-sponsor
- HQ: San Diego, CA
- Type: biotech
- Website: http://www.traconpharma.com

## Sources

- Official website: http://www.traconpharma.com
- ClinicalTrials.gov: trials led by Tracon Pharmaceuticals Inc.: https://clinicaltrials.gov/search?lead=Tracon%20Pharmaceuticals%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q30289078

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- drugs: [Envafolimab](https://onco.cc/drugs/envafolimab/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/tracon.json